Free Trial
NASDAQ:APGE

Apogee Therapeutics Q2 2023 Earnings Report

Apogee Therapeutics logo
$36.40 -0.48 (-1.30%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$36.38 -0.02 (-0.04%)
As of 05/28/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics EPS Results

Actual EPS
-$3.78
Consensus EPS
-$2.49
Beat/Miss
Missed by -$1.29
One Year Ago EPS
N/A

Apogee Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Apogee Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 28, 2023
Conference Call Time
12:00PM ET

Upcoming Earnings

Apogee Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Apogee Therapeutics Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Apogee Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apogee Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apogee Therapeutics and other key companies, straight to your email.

About Apogee Therapeutics

Apogee Therapeutics (NASDAQ:APGE), through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

View Apogee Therapeutics Profile

More Earnings Resources from MarketBeat